Abstract: Breast cancer is the most common malignant tumor in women. Regional lymph node status is an important prognostic indicator that guides staging of tumors and influences application of adjuvant therapy. Minimally invasive lymph node surgery in breast cancer begins with sentinel lymph node biopsy (SLNB), which is established based on the premise of a standardized operation as a safe and effective replacement for axillary lymph node dissection. The Committee of Breast Cancer Society of China Anti-Cancer Association invited authoritative experts nationwide to participate in the preparation of the Guidelines for Standardized Practice of Sentinel Lymph Node Biopsy in Breast Cancer based on evidence-based medicine, which focuses on the indications for SLNB, tracer selection and application, tissue specimen processing, axillary SLNB, neoadjuvant therapy and SLNB, and internal mammary SLNB. The guideline aims to provide the most effective references for practitioners to achieve the best outcomes for patients with breast cancer.